The U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering IRLAB’s drug candidate IRL1117

Gothenburg, Sweden, October 27, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company focused on discovering and developing new treatments for Parkinson’s disease, today announced that the U.S. Patent and Trademark Office (USPTO) intends to grant a patent for IRL1117, a drug candidate with the potential to revolutionize the treatment of the core symptoms of Parkinson’s disease. The patent is expected to remain in force until the early 2040s.

Nomination committee appointed for IRLAB’s annual general meeting 2027

IRLAB’s Preclinical Research Underpinning Linepemat Published in Peer-Reviewed Journal